Novo Nordisk is rated a strong buy, offering a 4.2% dividend yield and trading at a 40% discount to its fair value. Although growth is currently pressured by U.S. price cuts and competition, the company is expected to achieve double-digit growth from 2027 onward due to volume increases and product expansion. Its Wegovy franchise, including a leading pill, is outperforming competitors internationally, with significant pipeline milestones anticipated in 2026–2027. Dividend growth is projected to average 7.5% through 2030, with an estimated total return CAGR of 18–23% over five years.
Wells Fargo's economist forecasts GLP-1 weight-loss drugs like Ozempic and Mounjaro will reach about 90 million prescriptions, rivaling statins. This trend is driving demand for high-protein, low-volume foods suited for appetite-suppressed patients, ...
Bitcoin dropped to its lowest level since February, falling as much as 2.3% due to record outflows from spot Bitcoin ETFs totaling $2.3 to $2.8 billion and weakening institutional demand. Strategy's sale of 32 bitcoins, its first in nearly four years...
Novo Nordisk has launched the Wegovy pill in the United Arab Emirates, marking the first availability outside the US. The pill, containing semaglutide, is approved to reduce excess body weight by an average of 17% and lower the risk of major cardiova...
Novo Nordisk's oral GLP-1 weight-loss drug, Wegovy pill, continues to outsell Eli Lilly's competing tablet, Foundayo, with around 146,000 prescriptions in the week ending May 22. However, weekly prescription growth has slowed to 2% as the market adju...
Novo Nordisk began a share repurchase program on 6 May 2026, aiming to buy back up to DKK 15 billion worth of B shares over 12 months starting 4 February 2026. As of 29 May 2026, the company repurchased 17.9 million shares at an average price of DKK ...
